RecruitingNot ApplicableNCT02304913

Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy

Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial


Sponsor

Universität Duisburg-Essen

Enrollment

75 participants

Start Date

Jan 1, 2015

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Initial treatment with platinum-containing or taxane-based CTX (regardless of the the length of the CTX cycle)
  • Senological, gynecological or internistic tumors
  • Phantogeusia (on average ≥4 NRS)
  • Willingness to participate in the study and written informed consent

Exclusion Criteria8

  • Severe stomatitis
  • Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of drugs with taste disorders as side effects
  • Leucopenia/neutropenia
  • Intake of anticoagulants
  • Smoking
  • Severe physical or mental comorbidity (due to which the patient is unable to participate in the study)
  • Participation in other CAM treatments within the integrative oncology care
  • Participation in other studies on the effectiveness of interventions for oral complications

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHypoglossal acupuncture
OTHERSham acupuncture
BEHAVIORALDietary recommendations

Locations(3)

Department of Gynecology & Gynecologic Oncology, Evang. Kliniken Essen-Mitte

Essen, North Rhine-Westphalia, Germany

Universitätsklinikum Mannheim, Internistische Onkologie

Mannheim, Germany

Robert Bosch Krankenhaus Stuttgart

Stuttgart, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02304913


Related Trials